388
Participants
Start Date
February 24, 2023
Primary Completion Date
June 3, 2024
Study Completion Date
June 3, 2024
Oral semaglutide
Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Lead Sponsor
Novo Nordisk A/S
INDUSTRY